Interesting OCUL Put And Call Options For February 2026

Ocular Therapeutix (OCUL) is highlighted for two option strategies around the $12.37 stock price: a sell-to-open $11 put (bid $0.30) would set an effective purchase basis of $10.70, is ~11% out‑of‑the‑money, carries a 72% probability of expiring worthless and would yield 2.73% (15.80% annualized) if it does. A covered‑call using the $14 strike (bid $2.30) — ~13% premium — would produce a 31.77% total return if called at Feb 2026, has a 44% chance of expiring worthless and an 18.59% (107.72% annualized) YieldBoost; implied volatilities are 146% (put) and 135% (call) versus a 12‑month realized volatility of 67%.

Analysis

Market structure: The immediate winners are option premium sellers (vol sellers) and buyers willing to establish exposure to OCUL at a net basis below spot (cash‑secured put sellers). With IV at 135–146% vs realized 67%, the options market is pricing a large idiosyncratic binary (trial/FDA/secondary) risk; that inflates option cost and benefits liquidity providers and short‑vol strategies. Small‑cap biotech counterparties (retail long-only holders) are hurt if a dilutive secondary or adverse trial outcome occurs, compressing share price and increasing borrow costs.

Risk assessment: Tail risks are classic biotech events — negative trial data, FDA rejection, or an equity raise — any of which can gap >50% and vaporize short‑vol gains; a secondary within 90 days would be most damaging. Near term (days–weeks) IV can collapse on a non‑event; short term (months) binary outcomes dominate; long term (quarters) fundamentals (product commercialization, cash runway) govern survival. Hidden dependencies include liquidity/quote slippage on option execution and asymmetric skew (puts pricier than calls), implying higher downside risk than symmetric models show.

Trade implications: Prefer selling volatility selectively rather than naked directional bets. Use cash‑secured OCUL $11 puts (net basis $10.70) or buy OCUL and sell Feb‑2026 $14 covered calls to harvest premium and cap upside; size positions small (1–3% portfolio) and set mechanical stops (close if OCUL < $9.50 or IV spikes >200%). For broader exposure, pair OCUL long + short XBI (equal dollar) to isolate idiosyncratic outcome while hedging sector beta.

Contrarian angles: The market may be overpricing long‑dated IV — if no near‑term catalyst, vols should mean‑revert toward realized 67%, favoring short calendar/vertical spreads rather than outright naked short strangles. Conversely, consensus may underweight dilution risk; if an offering is announced, forced sellers and option assignment risk can amplify downside. Historical parallels (small‑cap biotechs pre‑secondary) show short‑vol strategies can blow up quickly; size and strict stops are essential.

Key Decisions for Investors

• Establish a small (1–2% portfolio) cash‑secured short at OCUL: sell-to-open 1 Feb‑2026 $11 puts at $0.30 (collect $30 per contract), target net basis $10.70; close if OCUL < $9.50 or if implied vol rises >200%.
• If comfortable owning shares, buy OCUL up to 2–3% position at market (~$12.37) and sell Feb‑2026 $14 covered calls at $2.30 to lock a 31.8% capped return to expiry; roll or close if OCUL > $16 or if material clinical/SEC filings appear.
• Trade volatility: sell near‑dated (30–90 day) vertical credit spreads (e.g., sell 1–2x 10–15% OTM calls or puts, buy farther OTM protection) sized to 0.5–1% risk, to exploit IV 2x realized while limiting tail risk; unwind on >15% underlying move/day.
• Pair trade: overweight OCUL via covered‑call structure (2% weight) and short XBI equal dollar (2%) to express idiosyncratic upside while neutralizing sector beta; reassess after any corporate filing or within 30–60 days of major trial readout.